Kindbody

Kindbody offers fertility monitoring and preservation services through more than 300 locations, including their own clinics as well via a network of partner clinics with COE (center of excellence). Its clinics and online support network provide gynecology and wellness services including fertility assessments, egg freezing, embryo freezing, in vitro fertilization (IVF), and LGBTQ fertility consultation among others.

The company offers egg freezing for USD 6,950 (excluding bloodwork, medication, and storage), which is below the industry average of USD 10,000-11,000. Kindbody also offers virtual fertility consultation for USD 150, fertility assessment and egg freezing assessment for USD 300, and male assessment with semen analysis for USD 250.

Kindbody launched its first consumer product— Kind at Home , and made its foray into the fertility test-kit market in January 2022. Kind at Home, which is a fertility hormone test kit for both women and men, is administered via a finger prick blood test. The test kit including personalized recommendations by Kindbody’s board-certified physicians costs USD 169. The test kit for women determines levels of seven reproductive hormones relating to ovulatory function, infertility, miscarriage, and menopause to indicate ovarian reserve and female reproductive health. The test kit for men also determines levels of seven reproductive hormones including testosterone to indicate male reproductive function and sexual health. The test kit provides comprehensive information on fertility windows with personalized physician-led recommendations on overall reproductive health through in-clinic or virtual appointments within the patient portal.

Kindbody plans to launch a sperm analysis kit and additional preconception, pregnancy, and postpartum products in the Spring of 2022.

Kindbody has expanded its own clinic network, having opened three in H1 2021, bringing its total to nine clinics as of June 2021, and is scheduled to open in 13 locations by the end of 2021. It opened facilities in; 1) Los Altos (March 2021; to increase accessibility to Silicon Valley employees), 2) Atlanta (April 2021), and 3) Austin (June 2021; shortly after the fund raise). In July 2021, Kindbody announced the launch of a full-service mobile fertility clinic and a retail location in Denver during Fall 2021. The new mobile clinic will offer fertility assessments and patient care services including monitoring and physician consultations. Moreover, the company planned to further expand its physical footprint, with over a dozen new openings, in 2022.

Following this Kindbody acquired Vios Fertility Institute and its chain of clinics in February 2022, which valued the company at USD 1.15 billion. The acquisition doubled Kindbody's national footprint to 26 clinics and Kindbody expects to expand this to 40 by the end of 2022. Kindbody and Vios Fertility Institute together performed nearly 10,000 fertility treatments and served thousands of patients in 2021, which they expected to double in 2022. In June 2022, Kindbody acquired Phosphorus Labs , a verticalized genetic testing platform providing clinical-grade genetic testing for genomic information access. The acquisition enabled Kindbody to incorporate genomics into patient care. Phosphorus Labs’ 8,000 sq ft lab in New Jersey is expected to bring down Kindbody's existing genetic testing and screening in-house for patient care later in 2022.

In August 2022, Kindbody acquired Alternative Reproductive Resources (ARR) , a gestational surrogacy agency to add gestational surrogacy as part of its product offerings and the company will absorb ARR’s employees to its KindEOS division–its in-house egg and embryo donor program.

Key customers and partnerships

In addition to its vast range of services, the company works with employers to make fertility care more affordable to its employees. In June 2021, the company claimed that it had around 45 employer clients, representing more than 150,000 covered lives.

Funding and financials

Kindbody reported seeing stable growth despite the Covid-19 pandemic, with June 2020 patient volumes being 30% higher than pre-pandemic levels. In February 2021, Kindbody appointed Cindy Gentry as its first Chief Commercial Officer, to lead the expansion of its employer benefits offerings.

Kindbody received a USD 25 million investment from Morgan Health—the healthcare arm of JPMorgan Chase bank—in May 2023, with funds being allocated to geographic expansion efforts. In March 2023, Kindbody raised USD 100 million from Perceptive Advisors, at a USD 1.8 billion valuation.